Why is Glenmark Pharma falling/rising?

As of 22-Aug, Glenmark Pharmaceuticals Ltd. is experiencing a decline in its stock price, currently at 1,936.55, which reflects a decrease of 3.45 points or 0.18%. The stock has underperformed its sector today by 0.52%, and its delivery volume has significantly decreased by 35.94% compared to the 5-day average, indicating falling investor participation. Over the past week, the stock has dropped by 5.02%, and while it has shown strong returns over the longer term, including a 20.37% increase year-to-date, the recent performance suggests some short-term challenges. The company maintains a low Debt to EBITDA ratio of 1.00 times and high institutional holdings at 38.3%, which may provide some stability and confidence among investors despite the current price drop.
In the broader market context, Glenmark's recent performance contrasts with the Sensex, which has gained 0.88% over the past week. While the stock has outperformed the benchmark over the last three years with a remarkable 423.46% increase, the short-term decline highlights a divergence from the overall market trend. The stock's performance over the last month shows a 10.11% decline, further emphasizing its recent struggles compared to the Sensex's slight decrease of 1.07%. This combination of underperformance in the short term, alongside a strong historical performance, suggests that while the company has solid fundamentals, current market sentiment may be weighing on its stock price.